AI platform launch puts CorVel (CRVL) in focus

CorVel (CRVL) has launched CorVel Connected, an AI powered technology platform embedded in its CareMC claims management system. The new platform gives claims professionals real time decision support and automation tools within their existing workflows.

The CorVel Connected launch comes as the share price sits at US$57.98, with a 30 day share price return of 6.93% but a 1 year total shareholder return decline of 46.69%, suggesting recent momentum contrasts with weaker long term outcomes.

If this AI rollout has you looking beyond a single name, it could be a good moment to scan for other companies riding similar themes through 32 healthcare AI stocks

With a value score of 3 and an estimated 39.45% intrinsic discount, CorVel’s recent share price weakness contrasts with its long run track record. Is this a mispricing, or are markets already baking in future growth?

Price to earnings of 28x, is it justified?

On a P/E of 28x, CorVel trades at a higher earnings multiple than the US Healthcare industry average of 24.6x, even as the share price sits at $57.98.

The P/E ratio compares the share price to earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a company like CorVel, which reported earnings growth of 19.9% over the past year and 14.9% per year over the past 5 years, a higher multiple can signal that the market is willing to pay up for that earnings profile.

CorVel’s 28x P/E looks expensive against the broader US Healthcare industry on 24.6x, yet more reasonable against its peer group, where the average multiple is 56.1x. That gap suggests investors are pricing CorVel at a premium to the sector overall, but at a discount to closer peers, which could reflect how the market weighs its earnings growth, high quality earnings and 28.1% Return on Equity against recent share price underperformance.

Result: Price-to-earnings of 28x (ABOUT RIGHT)

However, a stretched valuation, alongside a 46.69% 1 year total return decline, could signal sensitivity to execution missteps in CorVel Connected and broader workers’ compensation demand.

Another view, cash flow points to undervaluation

While the 28x P/E might look full, the SWS DCF model paints a different picture. On this view, CorVel at $57.98 is trading below an estimated future cash flow value of $95.76, which frames the current price as a discount rather than a stretch. Which lens do you consider more useful for a long term assessment?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CorVel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation, price returns and the AI rollout, sentiment on CorVel is clearly split. It makes sense to move quickly and review the underlying data yourself, weighing both the risks that concern investors and the potential rewards that attract them through 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If CorVel has your attention, do not stop here. The next opportunity could already be on your radar if you look in the right places.

• Target potential bargains by scanning companies that combine quality with attractive pricing through 53 high quality undervalued stocks.
• Prioritize resilience and support a lower-risk approach by checking stocks screened for more stable profiles using 72 resilient stocks with low risk scores.
• Hunt for potential future standouts before they are widely followed by reviewing a screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.